OnKure Therapeutics, Inc.

NASDAQ:OKUR

Biotechnology

Healthcare
$2.76 +0.23%

+$0.01 today

Market cap
$111.79M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$4.30
52W Low $1.91High $5.38

Volume 0.14M

Average 0.37M

Returns on capital

OnKure Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-105.9%

avg -8.1%

ROIC

-110.9%

avg -106.3%

ROA

-95.8%

avg -81.0%

Analysis

ROA is currently the strongest return metric at -95.8% versus its period average of -81.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Nicholas A. Saccomano

President, Chief Executive Officer & DirectorUSD 858K6711.16K0.08%

Samuel Agresta

Chief Medical OfficerUSD 640.6K530<0.01%

Jason A. Leverone

Chief Financial OfficerUSD 591.2K5218.50K0.14%

Isaac Manke

Senior VP of Business Development & DirectorUSD 60.5K490<0.01%

James Blake

Senior Vice President of Computational Drug Discovery————

Kevin S. Litwiler

Senior Vice President of DMPK & Clinical Pharmacology————

Mark L. Boys

Senior Vice President of Discovery Chemistry————

Rogan Nunn

General Counsel & Secretary————

Roberta Alton

Senior Vice President of Clinical Operations————

Dylan Hartley

Chief Scientific Officer—570<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 21, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

8

$5,630.13

Net Transaction Value

−$5,630.13

Net selling

Most Active

Saccomano Nicholas A

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 21, 26

Saccomano Nicholas A

Direct

Sell$258.8
Sep 21, 26

Leverone Jason A.

Direct

Sell$898.2
Jun 22, 26

Saccomano Nicholas A

Direct

Sell$378.1
Jun 22, 26

Leverone Jason A.

Direct

Sell$1.3K
Mar 23, 26

Leverone Jason A.

Direct

Sell$1.3K
Mar 23, 26

Saccomano Nicholas A

Direct

Sell$357.5
Dec 22, 25

Saccomano Nicholas A

Direct

Sell$258.2
Dec 22, 25

Leverone Jason A.

Direct

Sell$896.2

Summary

Insiders reported 0 buys worth $0.00 and 8 sells worth $5,630.13 over the last 12 months. That adds up to net selling of $5,630.13. Saccomano Nicholas A was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A0 analysts
Net IncomeN/AN/AN/A
N/A0 analysts
EBITN/AN/AN/A
N/A0 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does OnKure Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about OKUR's management, answered from reported figures.

Who manages OKUR?

OnKure Therapeutics, Inc. (OKUR) lists 10 active executives. The top listed executive is Isaac Manke, Senior VP of Business Development & Director.

Are OKUR insiders buying or selling?

Recent insider activity shows net buying of $12.50M.